A phase I open label dose escalation study for the safety and tolerability of AZD2171 [cediranib] in solid tumors in Japan.

Trial Profile

A phase I open label dose escalation study for the safety and tolerability of AZD2171 [cediranib] in solid tumors in Japan.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Cediranib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Jun 2009 Actual patient number (40) added as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top